CTNM Stock Overview
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Contineum Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.45 |
| 52 Week High | US$16.06 |
| 52 Week Low | US$13.90 |
| Beta | 0 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0.32% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| CTNM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.0% | 1.0% | -0.7% |
| 1Y | n/a | 11.6% | 22.3% |
Return vs Industry: Insufficient data to determine how CTNM performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CTNM performed against the US Market.
Price Volatility
| CTNM volatility | |
|---|---|
| CTNM Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CTNM has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CTNM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 31 | Carmine Stengone | www.contineum-tx.com |
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.
Contineum Therapeutics, Inc. Fundamentals Summary
| CTNM fundamental statistics | |
|---|---|
| Market cap | US$392.04m |
| Earnings (TTM) | US$3.15m |
| Revenue (TTM) | US$50.00m |
123.4x
P/E Ratio7.8x
P/S RatioIs CTNM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTNM income statement (TTM) | |
|---|---|
| Revenue | US$50.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$50.00m |
| Other Expenses | US$46.85m |
| Earnings | US$3.15m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 100.00% |
| Net Profit Margin | 6.29% |
| Debt/Equity Ratio | 0% |
How did CTNM perform over the long term?
See historical performance and comparison